Table 4: Studies examining NLR in association with clinicopathological characteristics of PTC.

Association foundNo association found

AgeLiu et al. [4] (lower NLR in patients < 45 years)
Lang et al. [6] (lower NLR in patients < 45 years)
Kim et al. [15] (lower NLR in patients ≥ 45 years)
Liu et al. [3]
Kim et al. [5]
Gong et al. [14]
Manatakis et al.

SexLiu et al. [3], Liu et al. [4], Kim et al. [5],
Lang et al. [6], Gong et al. [14]
Manatakis et al.

Tumour sizeLiu et al. [3], Kim et al. [5],
Lang et al. [6], Gong et al. [14]
Liu et al. [4], Cho et al. [8],
Kim et al. [15], Manatakis et al.

Extrathyroidal invasionManatakis et al.Liu et al. [3], Liu [4] Kim et al. [5],
Lang et al. [6], Kim et al. [15]

MultifocalityGong et al. [14], Manatakis et al.Liu et al. [3], Kim et al. [5], Lang et al. [6],
Kim et al. [15]

BilateralityManatakis et al.Lang et al. [6]

Lymphovascular invasionLiu et al. [3], Lang et al. [6], Kim et al. [15]

Lymph node metastasisGong et al. [14], Manatakis et al.Liu et al. [3], Liu et al. [4], Kim et al. [5],
Lang et al. [6], Kim et al. [15]

TNM stageLiu et al. [4] (stages I-II versus III-IV)
Lang et al. [6] (for stage I)
Gong et al. [14] (for patients ≥ 45 years)
Liu et al. [3]
Kim et al. [5]
Kim et al. [15]
Manatakis et al.

Histologic subtypeLang et al. [6], Manatakis et al.

ThyroiditisKim et al. [15] (lower NLR in Hashimoto)Liu et al. [3], Lang et al. [6],
Kocer et al. [16], Manatakis et al.

Recurrence riskLiu et al. [3]

PrognosisKim et al. [5] (for stages III-IV)Lang et al. [6], Cho et al. [8]